Published: 2019-09-25

Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy

Navneet O. Soni, Saroja V. Pawar, Sheetal Kale, Uday A. Mane, Pravin U. Bhosale, Komal Phandhare, Priya R. Bhosale, Smitha A. Patil


Diabetic nephropathy is global problem with several drugs into trial without much success the current article highlights the role of thiazolidinedione’s in diabetic nephropathy by scrutinizing and reconnoitring the cellular and intracellular mechanism and shielding action and the role of peroxisome proliferator-activated gamma receptors (PPARγ) receptors. Not only anti-diabetic action but renal protective effect with evidence based study has been highlighted. PPAR γ-is versatile target having numerous benefits and mainly preventing fibrosis in diabetic experimental model and some clinical case report yet, the benefits are not up to mark, since renal failure itself causes volume expansion and the thiazolidinedione’s (TZDs) also preserve salt and water and lead to congestive heart failure which constraints its clinical application. Dual activators and balaglitazone selective PPAR modulator are having upcoming potential for treatment of diabetic nephropathy. Further detail investigation on such drug is needed to explore. However adverse effect like heart failure, osteoporosis and volume expansion effect over-rides the beneficial effect thus limiting its clinical use of currently available TZDs.


Thiazolidinediones, Diabetic nephropathy, PPARγ

Full Text:



Furukawa M, Gohda T, Tanimoto M, Tomino Y. Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Scientific World J. 2013;2013:1-8.

Soni NO. Embryonic life of HDACs inhibitor-in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:345-59.

Soni NO. NADPH oxidase is novel drug in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:765-75.

Soni NO. TGF-β is novel drugs in diabetic nephropathy. World J Pharm Pharmaceutical Sci. 2017;6:622-45.

Soni NO. Drugs for diabetic nephropathy-full review. World J Pharm Pharmaceutical Sci. 2017;6:1958-2022.

Davis L, Guan Y, Zhang Y, Breyer RM, Breyer MD. Activity is associated with renal microvasculature. Am J Physiol Renal Physiol. 2001;281(6):1036-46.

Lee EY, Kim GT, Hyun M, Kim S, Seok S, Choi R, et al. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol Dial Transplant. 2012;27:4069-79.

Sarafidis PA, Georgianos PI, Lasaridis AN. PPAR-γ Agonism for cardiovascular and renal protection. Cardiovascular Therapeutic. 2011;29:377-84.

Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metab Clin Exp. 2001;50:1193-96.

Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metab Clin Exp. 2002;51:403-8.

Yotsumoto T, Naitoh T, Kanaki T, Matsuda M, Tsuruzoe N. A novel peroxisome proliferator-activated receptor (PPAR) gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPAR gamma activation. Metab Clin Exp. 2003;52:1633-7.

Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metab Clin Exp. 2004;53:1473-9.

Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol. 2005;16:638-45.

Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem. 2006;281:8748-55.

Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int. 2006;69:1756-64.

Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006;55:1666-77.

Katavetin P, Eiam-Ong S, Suwanwalaikorn S. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai. 2006;89:170-7.

Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, et al. Peroxisome Proliferator-activated receptor α/γ dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes. 2007;56:2036-45.

Yu X, Li C, Li X, Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci. 2007;96:346-56.

Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23:2750-60.

Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor- alpha- dependent manner in vitro and in vivo in mice. J Am Coll Cardiol. 2008;52:869-81.

Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest. 2009;89:47-58.

Flaquer M, Lloberas N, Franquesa M, Torras J, Vidal A, Rosa JL, et al. The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life Sci. 2010;87:147-53.

Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, et al. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol. 2010;32:393-402.

Atanasov AG, Wang JN, Gu SP, Bu J, Kramer MP, Baumgartner L, et al. Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta. 2013;1830:4813-9.

Huang KC, Cherng YG, Chen LJ, Hsu CT, Cheng JT. Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats. Horm Metab Res. 2014;46:240-4.

Jesse CR, Bortolatto CF, Wilhelm EA, Roman SS, Prigol M, Nogueira CW. The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice. J Appl Toxicol. 2014;34:25-32.

Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, et al. New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy. PPAR Res. 2014;2014:1-7.

Platt C, Coward RJ. Peroxisome proliferator activating receptor-γ and the podocyte. Nephrol Dial Transplant. 2017;32:423-33.

Cooper M, Warren AM. A promising outlook for diabetic kidney disease. Nature Reviews Nephrol. 2019;15:68-70.

Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol. 2007;292:1141-50.

Wang W, Liu F, Chen N. Peroxisome proliferator-activated receptor- γ (PPAR- γ ) agonists attenuate the profibrotic response induced by TGF- β 1 in renal interstitial fibroblasts. Mediators Inflamm. 2007;2007:1-7.

Corrales P, Izquierdo-Lahuerta A, Medina-Gomez G. Maintenance of kidney metabolic homeostasis by PPAR gamma. Int J Mol Sci. 2018;19(7):e2063.

Lee EY, Kim GT, Hyun M, Kim S, Seok S, Choi R, et al. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes. Nephrol Dialysis Transplant. 2012;27:4069-79.

Sugawara A, Uruno A, Matsuda K, Saito-Ito T, Funato T, Saito-Hakoda A, et al. Effects of PPARγ agonists against vascular and renal dysfunction. Curr Mol Pharmacol. 2012;5:248-54.

Yang J, Zhou Y, Guan Y. PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hypertens. 2012;21:97-105.

Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 2001;60:14-30.

Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy-relevance to renoprotection. Nat Clin Pract Nephrol. 2005;1:33-43.

Chung BH, Lim SW, Ahn KO, Sugawara A, Ito S, Choi BS, et al. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrol (Carlton). 2005;10:S40-3.

Yang J, Zhang D, Li J, Zhang X, Fan F, Guan Y. Role of PPAR gamma in renoprotection in type 2 diabetes: molecular mechanisms and therapeutic potential. Clin Sci. 2009;116:17-26.